Cargando…
Shp1 in Solid Cancers and Their Therapy
Shp1 is a cytosolic tyrosine phosphatase that regulates a broad range of cellular functions and targets, modulating the flow of information from the cell membrane to the nucleus. While initially studied in the hematopoietic system, research conducted over the past years has expanded our understandin...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300250/ https://www.ncbi.nlm.nih.gov/pubmed/32596156 http://dx.doi.org/10.3389/fonc.2020.00935 |
_version_ | 1783547549492183040 |
---|---|
author | Varone, Alessia Spano, Daniela Corda, Daniela |
author_facet | Varone, Alessia Spano, Daniela Corda, Daniela |
author_sort | Varone, Alessia |
collection | PubMed |
description | Shp1 is a cytosolic tyrosine phosphatase that regulates a broad range of cellular functions and targets, modulating the flow of information from the cell membrane to the nucleus. While initially studied in the hematopoietic system, research conducted over the past years has expanded our understanding of the biological role of Shp1 to other tissues, proposing it as a novel tumor suppressor gene functionally involved in different hallmarks of cancer. The main mechanism by which Shp1 curbs cancer development and progression is the ability to attenuate and/or terminate signaling pathways controlling cell proliferation, survival, migration, and invasion. Thus, alterations in Shp1 function or expression can contribute to several human diseases, particularly cancer. In cancer cells, Shp1 activity can indeed be affected by mutations or epigenetic silencing that cause failure of Shp1-mediated homeostatic maintenance. This review will discuss the current knowledge of the cellular functions controlled by Shp1 in non-hematopoietic tissues and solid tumors, the mechanisms that regulate Shp1 expression, the role of its mutation/expression status in cancer and its value as potential target for cancer treatment. In addition, we report information gathered from the public available data from The Cancer Genome Atlas (TCGA) database on Shp1 genomic alterations and correlation with survival in solid cancers patients. |
format | Online Article Text |
id | pubmed-7300250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73002502020-06-26 Shp1 in Solid Cancers and Their Therapy Varone, Alessia Spano, Daniela Corda, Daniela Front Oncol Oncology Shp1 is a cytosolic tyrosine phosphatase that regulates a broad range of cellular functions and targets, modulating the flow of information from the cell membrane to the nucleus. While initially studied in the hematopoietic system, research conducted over the past years has expanded our understanding of the biological role of Shp1 to other tissues, proposing it as a novel tumor suppressor gene functionally involved in different hallmarks of cancer. The main mechanism by which Shp1 curbs cancer development and progression is the ability to attenuate and/or terminate signaling pathways controlling cell proliferation, survival, migration, and invasion. Thus, alterations in Shp1 function or expression can contribute to several human diseases, particularly cancer. In cancer cells, Shp1 activity can indeed be affected by mutations or epigenetic silencing that cause failure of Shp1-mediated homeostatic maintenance. This review will discuss the current knowledge of the cellular functions controlled by Shp1 in non-hematopoietic tissues and solid tumors, the mechanisms that regulate Shp1 expression, the role of its mutation/expression status in cancer and its value as potential target for cancer treatment. In addition, we report information gathered from the public available data from The Cancer Genome Atlas (TCGA) database on Shp1 genomic alterations and correlation with survival in solid cancers patients. Frontiers Media S.A. 2020-06-11 /pmc/articles/PMC7300250/ /pubmed/32596156 http://dx.doi.org/10.3389/fonc.2020.00935 Text en Copyright © 2020 Varone, Spano and Corda. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Varone, Alessia Spano, Daniela Corda, Daniela Shp1 in Solid Cancers and Their Therapy |
title | Shp1 in Solid Cancers and Their Therapy |
title_full | Shp1 in Solid Cancers and Their Therapy |
title_fullStr | Shp1 in Solid Cancers and Their Therapy |
title_full_unstemmed | Shp1 in Solid Cancers and Their Therapy |
title_short | Shp1 in Solid Cancers and Their Therapy |
title_sort | shp1 in solid cancers and their therapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300250/ https://www.ncbi.nlm.nih.gov/pubmed/32596156 http://dx.doi.org/10.3389/fonc.2020.00935 |
work_keys_str_mv | AT varonealessia shp1insolidcancersandtheirtherapy AT spanodaniela shp1insolidcancersandtheirtherapy AT cordadaniela shp1insolidcancersandtheirtherapy |